Value of urine lipoarabinomannan grade and second test for optimizing clinic-based screening for HIV-associated pulmonary tuberculosis

Journal of Acquired Immune Deficiency Syndromes

Volumn 68, Issue 3, 2015, Pages 274-280

  Drain, Paul K ^a,b   Losina, Elena ^a,c   Coleman, Sharon M ^d   Giddy, Janet ^e   Ross, Douglas ^f   Katz, Jeffrey N ^c   Bassett, Ingrid V ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e MCCORD HOSPITAL   (South Africa)

^f St Mary's Hospital   (South Africa)

Author keywords

HIV AIDS; lipoarabinomannan; screening; South Africa; tuberculosis; urine

Indexed keywords

CD4 ANTIGEN; LIPOARABINOMANNAN; LIPOPOLYSACCHARIDE;

ACID FAST BACTERIUM; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CARBOHYDRATE ANALYSIS; CD4 LYMPHOCYTE COUNT; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS ASSOCIATED PULMONARY TUBERCULOSIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTPATIENT; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; SPUTUM CULTURE; URINALYSIS; URINE LEVEL; AIDS-RELATED OPPORTUNISTIC INFECTIONS; COMPLICATION; EVALUATION STUDY; MASS SCREENING; POINT OF CARE SYSTEM; PROCEDURES; TUBERCULOSIS, PULMONARY; URINE; YOUNG ADULT;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HIV INFECTIONS; HUMANS; LIPOPOLYSACCHARIDES; MALE; MASS SCREENING; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84923651633     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000436     Document Type: Article

References (30)

1. World Health Organization. Treatment of Tuberculosis: Guidelines. 4th ed. Geneva, Switzerland: World Health Organization; 2010.
2. Drain PK, Hyle EP, Noubary F, et al. Diagnostic point-of-care tests in resource-limited settings. Lancet Infect Dis. 2014; 14: 239-249.
3. World Health Organization. Systematic Screening for Active Tuberculosis: Principles and Recommendations. Geneva, Switzerland: World Health Organization; 2013.
4. Ayles H, Schaap A, Nota A, et al. Prevalence of tuberculosis, HIV and respiratory symptoms in two Zambian communities: implications for tuberculosis control in the era of HIV. PLoS One. 2009; 4: e5602.
5. Lawn SD, Edwards DJ, Kranzer K, et al. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS. 2009; 23: 1875-1880.
6. Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis. 2010; 51: 823-829.
7. Hassim S, Shaw PA, Sangweni P, et al. Detection of a substantial rate of multidrug-resistant tuberculosis in an HIV-infected population in South Africa by active monitoring of sputum samples. Clin Infect Dis. 2010; 50: 1053-1059.
8. Keeler E, Perkins MD, Small P, et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature. 2006; 444 (suppl 1): 49-57.
9. Saito S, Howard AA, Reid MJ, et al. TB diagnostic capacity in sub-Saharan African health care settings. J Acquir Immune Defic Syndr. 2012; 61: 216-220.
10. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. New Engl J Med. 2010; 363: 1005-1015.
11. Churchyard G, McCarthy K, Fielding KL, et al. Effect of Xpert MTB/RIF on early mortality in adults with suspected TB: a pragmatic randomized trial. Paper presented at: Conference on Retroviruses and Opportunistic Infections; March 2014; Boston, MA. (Abstract #95).
12. Stop TB Program, World Health Organization. Reach the 3 million. Geneva, Switzerland: World Health Organization; 2014.
13. Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb). 2003; 83: 91-97.
14. Reither K, Saathoff E, Jung J, et al. Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis. BMC Infect Dis. 2009; 9: 141.
15. Shah M, Variava E, Holmes CB, et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIV prevalence setting. J Acquir Immune Defic Syndr. 2009; 52: 145-151.
16. Dheda K, Davids V, Lenders L, et al. Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS One. 2010; 5: e9848.
17. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis. 2012; 12: 103.
18. Dorman S, Manabe Y, Nicol M, et al. Accuracy of Determine TB-Lipoarabinomannan lateral flow test for diagnosis of TB and HIV+ adults: Interim results from a multicenter study. Paper presented at: 19th Conference on Retroviruses and Opportunistic Infection; March 2012; Seattle, WA. Abstract #149aLB.
19. Peter JG, Theron G, van Zyl Smit R, et al. Diagnostic accuracy of a urine LAM strip-test for TB detection in HIV-infected hospitalized patients. Eur Respir J. 2012; 40: 1211-1220.
20. Van Rie A, Jong E, Mikhwanazi M, et al. Diagnosing TB in those hardest to diagnose: urine lipoarabinomannan for suspects of disseminated and extrapulmonary TB. Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections; March 2013; Atlanta, GA (Abstract #841).
21. Drain PK, Losina E, Coleman SM, et al. Diagnostic accuracy of a pointof-care urine test for tuberculosis screening among newly-diagnosed HIV-infected adults: a prospective, clinic-based study. BMC Infect Dis. 2014; 14: 110.
22. Department of Health. The South African Antiretroviral Treatment Guidelines 2013. Pretoria, South Africa: Republic of South African; 2013.
23. Liu TT, Wilson D, Dawood H, et al. Inaccuracy of death certificate diagnosis of tuberculosis and potential underdiagnosis of TB in a region of high HIV prevalence. Clin Dev Immunol. 2012; 2012: 937013.
24. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more Correlated receiver operating characteristic curves: a Nonparametric approach. Biometrics. 1988; 44: 837-845.
25. Lawn SD, Kerkhoff AD, Vogt M, et al. Diagnostic accuracy of a lowcost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012; 12: 201-209.
26. Shah M, Ssengooba W, Armstrong D, et al. Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals. AIDS. 2014; 28: 1307-1314.
27. Drain PK, Gounder L, Grobler A, et al. Point-of-care urine lipoarabinomannan (LAM) for diagnosis and treatment response of pulmonary tuberculosis in sputum smear-negative suspects. Paper presented at: 44th Union World Conference on Lung Health; November 2013; Paris, France (Abstract #PC-556-02).
28. Lawn SD, Dheda K, Kerkhoff AD, et al. Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infect Dis. 2013; 13: 407.
29. Nakiyingi L, Moodley VM, Manabe YC, et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr. 2014; 66: 270-279.
30. Balcha TT,Winqvist N, Sturegard E, et al. Detection of lipoarabinomannan in urine for identification of active tuberculosis among HIV-positive adults in Ethiopian health centres. Trop Med Int Health. 2014; 19: 734-742